Cargando…
Clinical Safety and Tolerability of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Botulinum Neurotoxin Subtype A2, in Comparison with Subtype A1 Toxins
All the botulinum type A neurotoxins available for clinical use are of the A1 subtype. We developed a subtype A2 low-molecular-weight (150 kD (kilo Dalton)) neurotoxin (A2NTX) with less spread and faster entry into the motor nerve terminal than A1 in vitro and in vivo. Preliminary clinical studies s...
Autores principales: | Takeuchi, Toshiaki, Okuno, Tsuyoshi, Miyashiro, Ai, Kohda, Tomoko, Miyamoto, Ryosuke, Izumi, Yuishin, Kozaki, Shunji, Kaji, Ryuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8623066/ https://www.ncbi.nlm.nih.gov/pubmed/34822610 http://dx.doi.org/10.3390/toxins13110824 |
Ejemplares similares
-
A Pilot Study of A2NTX, a Novel Low-Molecular-Weight Neurotoxin Derived from Subtype A2 for Post-Stroke Lower Limb Spasticity: Comparison with OnabotulinumtoxinA
por: Kaji, Ryuji, et al.
Publicado: (2022) -
Botulinum Neurotoxin Type A Subtype 2 Confers Greater Safety than Subtype 1
in a Rat Parkinson’s Disease Model
por: ITAKURA, Masanori, et al.
Publicado: (2014) -
Historical Perspectives and Guidelines for Botulinum Neurotoxin Subtype Nomenclature
por: Peck, Michael W., et al.
Publicado: (2017) -
Isolation and Characterization of the Novel Botulinum Neurotoxin A Subtype 6
por: Moritz, Molly S., et al.
Publicado: (2018) -
Crystal structure of the catalytic domain of botulinum neurotoxin subtype A3
por: Leka, Oneda, et al.
Publicado: (2021)